Single sST2 protein measurement predicts adverse outcomes at 1-year follow-up in patients with chronic heart failure.

Pol Arch Med Wewn 2014 21;124(9):452-8. Epub 2014 Jul 21.

Introduction: sST2 protein is a new biomarker. Its prognostic value in chronic heart failure (CHF) is still unclear.

Objectives: The aim of the study was to evaluate the value of sST2 protein in patients with CHF during 1-year follow-up after hospitalization for prediction of adverse events: cardiovascular death, rehospitalization, an increase in diuretic doses, and/or worsening of the New York Heart Association functional class, defined as the composite endpoint.

Patients And Methods: The study involved 145 consecutive patients (mean age, 62.16 ±11.25 y; men, 82.76%) with left ventricular (LV) ejection fraction of 30% or less and symptomatic CHF. We analyzed clinical and biochemical data along with the serum concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and sST2. The optimal cut-off points for significant predictors of the composite endpoint were determined using receiver operating characteristi c curves.

Results: Patients with elevated levels of sST2 and NT-proBNP had more than a 4-fold higher risk of composite endpoint (odds ratio [OR], 4.033; 95%CI, 1.540-10.559) compared with patients in whom both biomarkers were below the cut-off points. The C-statistic for predicting the composite endpoint was improved when both biomarkers were incorporated into the model (C-statistic, 0.692; P = 0.0001) compared with an individual analysis for NT-proBNP (C-statistic, 0.606; P = 0.009) and sST2 (C-statistic, 0.613; P = 0.003). Moreover, after the addition of sST2 to NT-proBNP, the continuous net reclassification improvement index (OR, 0.256; 95% CI, 0.090-0.401; P = 0.007) and the integrated discrimination improvement index (OR, 0.104; 95% CI 0.011-0.221; P = 0.007) significantly improved.

Conclusions: A single measurement of sST2 levels on admission in patients with poor LV systolic function and stable CHF is useful in short-term risk stratification and, in combination with NT-proBNP, it could be more useful in identifying patients with unfavorable c ourse of CHF.

Download full-text PDF

Source
http://dx.doi.org/10.20452/pamw.2403DOI Listing
November 2015

Publication Analysis

Top Keywords

sst2 protein
12
composite endpoint
12
chronic heart
8
sst2 nt-probnp
8
1-year follow-up
8
cut-off points
8
heart failure
8
sst2
7
patients
7
chf
5
nt-probnp
5
30% symptomatic
4
analyzed clinical
4
chf analyzed
4
c-statistic 0606
4
symptomatic chf
4
nt-probnp c-statistic
4
analysis nt-probnp
4
serum concentrations
4
0692 00001
4

Similar Publications

Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.

Acta Cardiol 2018 Feb 25;73(1):41-48. Epub 2017 Sep 25.

b Department of Cardiology , Tianjin Union Medical Center, Nankai University Affiliated Hospital , Tianjin , P.R. China.

Objective: The aim of this study was to compare sST2 at admission with N-terminal pro B-type natriuretic peptide (NT-proBNP) in prognostic accuracy among different types of heart failure (HF) and clarifying the enhanced prognostic value in patients with HF by the combination of the two biomarkers.

Methods And Results: A total of 164 consecutive patients admitted to our institution for HF were divided into three groups of HF with reduced ejection fraction (HFrEF), HF with mid-range ejection fraction (HFmrEF) and HF with preserved ejection fraction (HFpEF). Circulating sST2 and NT-proBNP were measured using the enzyme-linked immunosorbent assay (ELISA). Read More

View Article and Full-Text PDF
February 2018

sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.

J Am Coll Cardiol 2018 11;72(19):2309-2320

Massachusetts General Hospital, Harvard Clinical Research Institute, Boston, Massachusetts.

Background: Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to inflammation and fibrosis.

Objectives: This study assessed the independent prognostic value of sST2 in chronic heart failure (HF).

Methods: Individual patient data from studies that assessed sST2 for risk prediction in chronic HF, together with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT), were retrieved. Read More

View Article and Full-Text PDF
November 2018

Soluble ST2 protein in the short-term prognosis after hospitalisation in chronic systolic heart failure.

Kardiol Pol 2014 20;72(8):725-34. Epub 2014 May 20.

Klinika Kardiologii, Uniwersytet Medyczny w Łodzi, Łódź.

Background: The prognosis in patients with chronic heart failure (CHF) is poor. ST2 protein is a promising prognostic biomarker for CHF. ST2 belongs to the cardioprotective signalling pathway involving interleukin-33 and its concentration in the serum depends on the biomechanical stress of cardiomyocytes (biomechanical strain). Read More

View Article and Full-Text PDF
December 2016

Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions.

BMC Cardiovasc Disord 2020 04 30;20(1):208. Epub 2020 Apr 30.

Key laboratory of Geriatrics, Shengli Clinical Medical College of Fujian Medical University, Fujian Institute of Clinical Geriatrics, No.134, Road Dongjie, District Gulou, Fuzhou, 350001, P.R. China.

Background: This study sought to compare the predictive value of NT-proBNP, sST2 and MMPs in HF with different ejection fractions from a population in southern China.

Methods: A cross-sectional study was conducted on 113 HF patients admitted to Fujian Provincial Hospital from December 2016 to March 2018.The patients were divided into three subgroups: 60 cases in HFpEF group (LVEF≥50%), 28 cases in HFmrEF group (41% ≤ LVEF≤49%) and 25 cases in HFrEF group (LVEF≤40%). Read More

View Article and Full-Text PDF
April 2020